Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 27, 2023

Efficacy of Aromatase Inhibition With and Without the Src Inhibitor Saracatinib in Advanced Breast Cancer Therapy

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
Breast Cancer Res Treat 2023 Mar 02;[EPub Ahead of Print], AJ Oswald, SN Symeonides, D Wheatley, S Chan, AM Brunt, K McAdam, P Schmid, S Waters, C Poole, C Twelves, T Perren, J Bartlett, T Piper, EM Chisholm, M Welsh, R Hill, LEM Hopcroft, P Barrett-Lee, DA Cameron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading